Clinical Trial Update: CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the combination of CAR T-cell therapy with glofitamab for relapsed/refractory diffuse large B-cell lymphoma with high…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CAR T-cell therapy (unspecified)
• Columvi (glofitamab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Large B-cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING